Related Experiment Video
Updated: Dec 1, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Prediction-Determining Outcomes and Their Predictors in Atrial Fibrillation Patients Receiving Multicomponent
E N Krivosheeva1, E P Panchenko1, E S Kropacheva1
1National medical research center of cardiology of the Ministry of healthcare of the Russian Federation, Moscow.
Insights
This study identified key predictors for cardiovascular and bleeding complications in atrial fibrillation patients undergoing PCI with antithrombotic therapy. Growth-differentiation factor 15 (GDF-15) and PAI-1 levels, along with reduced DOAC dose, predict cardiovascular events, while the PRECISE-DAPT score predicts bleeding.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Patients with ischemic heart disease (IHD) and atrial fibrillation (AF) require multicomponent antithrombotic therapy (MAT) for percutaneous coronary intervention (PCI), placing them at high risk for thrombotic and hemorrhagic complications.
- Identifying novel risk factors is crucial for predicting outcomes in this high-risk population.
- Direct oral anticoagulants (DOACs) are commonly used in MAT regimens.
Purpose of the Study:
- To identify clinical, angiographic, and biochemical predictors of cardiovascular complications (CVC) and hemorrhagic complications in patients with IHD and AF receiving MAT for elective PCI.
- To analyze predictors for CVC, coronary events, and bleeding separately.
- To evaluate the prognostic significance of biomarkers such as GDF-15, D-dimer, TAFI, and PAI-1.
Main Methods:
- A cohort of 207 patients with IHD and AF receiving DOAC-based MAT for elective PCI were analyzed.
- Follow-up duration was a median of 12 months.
- Endpoints included a composite of CVCs (cardiovascular death, ischemic stroke, venous thromboembolism, ACS, unscheduled PCI), coronary events (ACS, unscheduled PCI), and BARC type 2-5 bleeding. Biomarkers were measured on admission. Cox regression was used for analysis.
Main Results:
- The incidence of CVCs was 16.4%. Independent predictors of CVC included reduced DOAC dose (OR 2.5), GDF-15 >1191 pg/ml (OR 3.76), and PAI-1 >13.2 U/ml (OR 2.67).
- The incidence of coronary complications was 9.2%. Predictors included SYNTAX score >26.5 (OR 4.5), PCI for chronic coronary occlusion (OR 3.21), and GDF-15 >1191 pg/ml (OR 4.70).
- The incidence of bleeding was 26.1%. The only independent predictor was a total PRECISE-DAPT score >30 (OR 3.22).
Conclusions:
- Reduced DOAC dose, elevated GDF-15, and elevated PAI-1 are independent predictors of CVC in IHD and AF patients undergoing PCI with MAT.
- High SYNTAX score, PCI for chronic coronary occlusion, and elevated GDF-15 predict coronary complications.
- The PRECISE-DAPT score is a significant predictor of bleeding complications in this patient group.
Abstract:
Aim Searching for clinical, angiographic, and biochemical predictors of cardiovascular complications (CVC) and hemorrhagic complications in patients with atrial fibrillation (AF) receiving a multicomponent antithrombotic therapy (MAT) for an elective percutaneous coronary intervention (PCI). Patients with ischemic heart disease (IHD) and AF who require MAT for PCI are at a high risk of thrombotic complications (stroke, systemic embolism, coronary events) and hemorrhage. This warrants searching for new risk factors determining prediction of the outcome.Materials and methods This study included 207 patients (146 males aged 70.1±8.3 years) with IHD and AF who received direct oral anticoagulants (DOAC) as a part of their MAT therapy. Median duration of the follow-up was 12 [8.0; 12.0] months. The efficacy endpoint was a sum of CVCs combining cardiovascular death, ischemic stroke, venous thromboembolic complications, acute coronary syndrome (ACS), and requirement for an unscheduled PCI. "Coronary events", including ACS and requirement for an unscheduled PCI were analyzed separately. The safety endpoint was BARC type 2-5 bleeding. Upon admission, biomarkers (growth-differentiation factor 15 (GDF-15), D-dimer, thrombin-activated fibrinolysis inhibitor (TAFI), and plasminogen activator inhibitor-1 (PAI-1)) were measured for all patients. Searching for prognostically significant indexes was performed with the Cox proportional hazards regression.Results Incidence of all CVCs was 16.4 %. Independent predictors of CVC included the DOAC treatment at a reduced dose (odds ratio (OR) 2.5 at 95 % confidence interval (CI) 1.02-6.15; p=0.0454), GDF-15 >1191 pg /ml (OR 3.76 at 95 % CI, 1.26-11.18; p=0.0172), PAI-1 >13.2 U/ml (OR 2.67 at 95 % CI, 1.13-6,26; p=0.0245). Incidence of coronary complications was 9.2 %. Independent predictors of coronary complications included a SYNTAX index >26.5 (OR 4.5 at 95 % CI, 1.45-13.60; p=0.0090), PCI for chronic coronary occlusion (OR 3.21 at 95 % CI, 1.10-9.33; p=0.0326), a GDF-15 >1191 pg/ml (ОR 4.70 at 95 % CI, 1.32-16.81; p=0.0172). Incidence of BARC type 2-5 bleeding was 26.1 %. The only independent predictor for hemorrhage complications was the total PRECISE-DAPT score >30 (ОR 3.22; 95 % CI, 1.89-5.51; р<0.0001).Conclusion Three independent predictors of CVC were identified for patients with IHD and AF treated with MAT following an elective PCI: treatment with a reduced dose of DOAC, GDF-15 >1191 pg /ml, and PAI-1>13.2 U/ml. Independent predictors of coronary complications included a SYNTAX index >26.5, PCI for chronic coronary occlusion, and GDF-15 >1191 pg/ml. The factor associated with a risk of bleeding was the total PRECISE-DAPT score >30.
More Related Videos
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Atherosclerosis III: Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Therapeutic Drug Monitoring: Affecting Factors

